Tetagam P pre-filled syringes
Marketed by Dexa Medica
Ingredients in every ml
| Tetanus Immunoglobulin | 250 IU |
Each package contains
Other details
| Flavour | None |
W.H.O. classification
| ATC Level 1 | J - Antiinfectives for systemic use |
| ATC Level 2 | J06 - Immune Sera and Immunoglobulins |
| ATC Level 3 | J06B - Immunoglobulins |
Warnings
Pregnancy
Lactation
Alcohol
Machinery
Available in
 |
Indonesia |
Dosage information
PROPHYLAXIS OF TETANUS PRONE WOUNDS
250 IU combinations with 0.5 ml of absorbed tetanus vaccine at contralateral sites of the body unless the risk is through to be extremely high. The dose may be increased to 500 IU in case of:
– Infected wounds where surgically appropriate treatment cannot be achieved within 24 hours
– Deep or contaminated wounds with tissue damage and reduced oxygen supply; as well as foreign-body injury (e.g., bites, stings or shots)
– Extensive burns, congelations
– Tissue necrosis
– Septicaemic abortion
In case of extensive burns it is advisable to administer a second injection of 250 IU Tetagam at 3-4 weeks interval if the patient is immunosuppressed or if active immunization with tetanus vaccine is contraindicated.
Children and Adults are to receive the same dose
THERAPY OF CLINICALLY MANIFEST TETANUS
Single doses of 3000 to 6000 IU (in combination with other appropriate clinical procedures). Regarding frequency, interval of injection and duration of therapy repeated doses depend on the clinical picture.
Indication
Postexposure prophylaxis
immediate prophylaxis after tetanus prone injuries in patients
– Not adequately vaccinated
– Whose immunisation status is not known with certainty
– With severe deficiency in antibody production.
Therapy of clinically manifest tetanus
Tetanus immunoglobulin should always be administered in conjunction with an active tetanus vaccination unless there are contraindications or confirmation of adequate vaccination.